Cargando…
Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
In recent years, therapeutic advances, together with new medication sequences and combinations, have improved outcomes for prostate cancer. For a long time, androgen deprivation therapy (ADT) has been the standard of care for newly diagnosed, metastatic prostate cancer, first as a standalone therapy...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287515/ https://www.ncbi.nlm.nih.gov/pubmed/30584309 http://dx.doi.org/10.2147/TCRM.S159824 |